Newsroom | 60416 results
Sorted by: Latest
-
CORRECTING and REPLACING EyeCare Partners Presents Latest Innovations in Eye Care at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 in Los Angeles
ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners will bring a strong lineup of clinical research and innovation to the upcoming annual ASCRS meeting....
-
Herbalife Welcomes Lynda Cloud to its Board of Directors
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the election of Lynda Cloud to its Board of Directors, effective April 23, 2025. This appointment reflects Herbalife’s continued commitment to innovation, digital transformation, and personalized wellness. Lynda Cloud’s decades of leadership across education, technology, and health sectors make her uniquely equipped to support Herbalife’s next chapter. Her dee...
-
City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting
LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for cancer by U.S. News & World Report, will present more than 74 chaired, plenary, educational, minisymposium, poster and other sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options at the AACR Annual Meeting, which st...
-
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and...
-
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced o...
-
Hippocratic AI Named to Newsweek’s America’s Greatest Startup Workplaces 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Hippocratic AI recognized for excellence in workplace culture and sustainable growth through a rigorous evaluation...
-
Longhorn Vaccines and Diagnostics Presents Compelling Data on LHNVD-303 Vaccine for Sepsis Related to Bacterial Infections at the World Vaccine Congress
BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening com...
-
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel leucine-rich repeat-containing protein 15 (LRRC15) antibody-drug conjugate (ADC) targeting multiple solid tumors, and ZL-1222, an innovative anti-PD-1/ interleukin-12 (IL-12) immunocytokine for cancer immunotherapy, during poster se...
-
Southern California Cities Honor Reproductive Partners Medical Group During National Infertility Awareness Week
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Reproductive Partners Medical Group (RPMG), a leading fertility clinic in Southern California and proud member of the Ivy Fertility network, has been honored with two city proclamations, from Beverly Hills and Westminster, recognizing National Infertility Awareness Week (NIAW). This recognition shines a spotlight on the impact of infertility and the need for increased awareness, support, and equitable access to fertility care. National Infertility Awarene...
-
New Research Explains Why Our Waistlines Expand in Middle Age
LOS ANGELES--(BUSINESS WIRE)--It’s no secret that our waistlines often expand in middle-age, but the problem isn’t strictly cosmetic. Belly fat accelerates aging and slows down metabolism, increasing our risk for developing diabetes, heart problems and other chronic diseases. Exactly how age transforms a six pack into a softer stomach, however, is murky. Now preclinical research by City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United Stat...